序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份85.1357.281.6730.41亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.1519.762.72356.78亿12三鑫医疗20.8121.623.6549.16亿 来源：金融界 采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙 ...

8月1日，采纳股份今日收盘23.56元，上涨3.38%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到80.61倍，创91天以来新低，总市值28.80亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份80.6154.251.5828.80亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.4637.96亿9维力医疗17.6918.902.2341.47亿10奥泰生物18.1519.141.4757.89亿11鱼跃医疗 19.8419.462.68351.37亿12安图生物20.0619.152.58228.74亿 来源：金融界 从行业 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Canan Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, the stock price of Canan Technology closed at 23.27 yuan, reflecting a 3.51% increase, with a rolling PE ratio of 79.62, marking a new low in 84 days, and a total market value of 2.845 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Canan Technology at the 100th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 24, Canan Technology experienced a net inflow of 10.8779 million yuan, with a total inflow of 1.5107 million yuan over the past five days [1] - The company specializes in the research, production, and sales of injection puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for the first quarter of 2025 show that Canan Technology achieved an operating income of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canar Medical Co., which has a current PE ratio of 77.63, marking a new low in 78 days, with a total market capitalization of 2.774 billion yuan [1][2] - Canar Medical's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canar Medical achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device industry is 52.71, with a median of 37.14, positioning Canar Medical at the 98th rank within the industry [1][2] - The number of shareholders for Canar Medical has increased to 7,596, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Technology Co., Ltd., particularly its high PE ratio compared to industry averages [1][2] - As of July 16, Canan's closing price was 22.24 yuan, with a rolling PE ratio of 76.09 times, significantly higher than the industry average of 51.87 times and the median of 37.48 times [1][2] - The company has a total market capitalization of 2.719 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - In terms of capital flow, Canan experienced a net outflow of 1.283 million yuan on July 16, with a total outflow of 3.9893 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for Q1 2025 show that Canan achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

7月7日，采纳股份今日收盘21.63元，上涨1.98%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到74.01倍，创63天以来新低，总市值26.44亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.42倍，行业中值37.44倍，采纳股份排 名第99位。 股东方面，截至2025年6月30日，采纳股份股东户数7494户，较上次减少177户，户均持股市值35.28万 元，户均持股数量2.76万股。 采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙头 企业。 最新一期业绩显示，2025年一季报，公司实现营业收入7270.93万元，同比-34.28%；净利润768.02万 元，同比-69.34%，销售毛利率31.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份74.0149.801.4526.44亿行业平均 51.4249.164.50106.60亿行业中值37.4437.842.5151.15亿1九安医疗10.2110.330 ...

Company Overview - Company name is采纳科技股份有限公司, primarily engaged in the research, production, and sales of injection puncture instruments and laboratory consumables [1] - Main products include medical devices, animal instruments, and laboratory consumables [1] - Recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province and a provincial-level leading enterprise in agricultural industrialization [1] Financial Performance - As of Q1 2025, the company reported revenue of 72.71 million yuan, a year-on-year decrease of 34.28% [1] - Net profit for the same period was 7.68 million yuan, down 69.34% year-on-year [1] - Gross profit margin stood at 31.15% [1] Market Position - The company's closing stock price was 21.21 yuan, down 1.49%, with a rolling PE ratio of 72.57 times [1] - Total market capitalization is 2.593 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times, the company ranks 99th [1][2] Institutional Holdings - As of Q1 2025, five institutions held shares in the company, with a total holding of 25.89 million shares valued at 57.1 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Co., which operates in the medical device industry, showing a significant decline in revenue and profit in the latest quarterly report [1][2] - As of June 19, Canan Co. closed at 19.96 yuan, down 2.59%, with a rolling PE ratio of 68.29, significantly higher than the industry average of 48.08 and the median of 36.05, ranking 99th in the industry [1][2] - The total market capitalization of Canan Co. is 2.44 billion yuan, with 5 institutions holding a total of 25.89 million shares valued at 571 million yuan [1] Group 2 - In the first quarter of 2025, Canan Co. reported revenue of 72.71 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.68 million yuan, down 69.34%, with a gross profit margin of 31.15% [1] - The company specializes in the research, production, and sales of injection and puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Technology Co., Ltd., which operates in the medical device industry [1][2] - As of May 22, Canan's stock closed at 20.55 yuan, down 1.82%, with a rolling PE ratio of 70.31 times, and a total market capitalization of 2.512 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Canan at the 100th position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, five institutions hold shares in Canan, with a total of 25.8895 million shares valued at 571 million yuan [1] - Canan's main business includes the research, production, and sales of injection and puncture devices and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for the first quarter of 2025 show that Canan achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Group 1 - The closing price of Canan Co., Ltd. on May 14 was 19.99 yuan, down 2.06%, with a rolling PE ratio of 68.40 times and a total market value of 2.444 billion yuan [1] - In the medical device industry, the average PE ratio is 49.84 times, and the median is 36.65 times, placing Canan Co., Ltd. at the 98th position in the industry ranking [1] - The main business of Canan Co., Ltd. includes the research, production, and sales of injection puncture instruments and laboratory consumables, with key products being medical devices, animal instruments, and laboratory consumables [1] Group 2 - For the first quarter of 2025, Canan Co., Ltd. reported operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] - The company has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province and a provincial-level leading enterprise in agricultural industrialization [1]